Oramed Pharmaceuticals (NASDAQ: ORMP) was established in 2006, and has developed a unique proprietary platform technology that allows for the oral delivery of drugs presently administered only via injection. Oramed has an experienced management team with many years of business and pharmaceutical experience, and is backed by world-class scientific experts. From the companyâs inception, Oramed has successfully tested its technology via various animal and human studies on its two flagship products, an orally ingestible insulin capsule, ORMD-0801, and an oral GLP-1 analog (exenatide) capsule, ORMD-0901. Source
No articles found.
A patient that is diagnosed with cancer today will have a genetic screen on their ...
A patient that is diagnosed with cancer today w...
Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pi...
Applied Therapeutics is a clinical-stage biopha...
BioLineRx is a clinical-stage biopharmaceutical company focused on oncology. The C...
BioLineRx is a clinical-stage biopharmaceutical...
uniQure is delivering on the promise of gene therapy -- single treatments with pot...
uniQure is delivering on the promise of gene th...
Join the National Investor Network and get the latest information with your interests in mind.